Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer

Pembrolizumab, or anti-programmed death receptor 1 antibody, is an immune checkpoint inhibitor that can cause immune-related adverse events. We herein report for the first time the progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagata, Satoshi, Kageyama, Kazunori, Takayasu, Shinobu, Asari, Yuko, Makita, Koshi, Terui, Ken, Daimon, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949454/
https://www.ncbi.nlm.nih.gov/pubmed/31462588
http://dx.doi.org/10.2169/internalmedicine.3008-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949454/
https://www.ncbi.nlm.nih.gov/pubmed/31462588
http://dx.doi.org/10.2169/internalmedicine.3008-19

Ejemplares similares